Intelligene Inc
TTPEX:783214.40
TWD
-0.05
(-0.35%)
ISIN
TW0007832008
Return %
Stock
S&P 500
1Y
7.06
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Hsien Lung Huang
- Sector
- Health technology
- Industry
- Pharmaceuticals: generic
- Address
- Taipei Taiwan
- Website
- intelli-gene.com
- Similar Companies
- Business
- Intelligene Inc. is a Taiwan-based biotechnology company focused on the discovery, development, and contract manufacturing of advanced RNA-based therapeutics and nanocarrier drug delivery systems. Founded in 2023 and headquartered in Taipei, Taiwan, the company operates across the biopharmaceutical and contract development sectors, utilizing proprietary bioinformatics and RNA interference (siRNA) technologies to engineer targeted therapeutics for infectious respiratory diseases and other high-unmet-need clinical indications. Intelligene Inc. offers a specialized portfolio of therapeutic pipelines, delivery platforms, and bioprocess services, including IG-001, a small interfering RNA therapeutic candidate utilizing lipid nanoparticle technology for the treatment of SARS-CoV-2 (COVID-19); IG-002, a broad-spectrum siRNA candidate utilizing engineered exosome technology for the treatment of influenza; proprietary Lipid Nanoparticle (LNP) formulation and encapsulation platforms designed for efficient intracellular nucleic acid delivery; engineered exosome platforms providing biocompatible, non-immunogenic delivery systems for extrahepatic and pulmonary tissue targeting; and biopharmaceutical Contract Development and Manufacturing Organization (CDMO) services comprising sequence design, formulation development, analytical characterization, scale-up, and pilot-scale GMP manufacturing of RNA payloads and delivery vehicles. The company serves global pharmaceutical enterprises, biotechnology developers, and academic research institutions, maintaining corporate headquarters and GMP pilot production facilities in Taipei, Taiwan, with international research and clinical operations supported by subsidiaries in Australia and the United States. In recent operational developments, Intelligene Inc. listed its shares on the Taipei Exchange (TPEX: 7832) Emerging Stock Board in May 2025. In addition, the company has broadened its global clinical collaborations through strategic development partnerships with Australia-based research institutions, including the Kirby Institute and Griffith University, securing grant support from Australia's Biomedical Translation Bridge (BRIDGE) program to advance clinical evaluation of its lead siRNA candidate, while operationalizing its specialized Taipei GMP pilot facility to expand commercial CDMO and formulation capabilities.